å»è¬åå ¬è¡šãããæŽå¯
泚å°å¯èœãª å»è¬åããªããªãŒã·ã¹ãã çµå£è¬é éã·ã¹ãã 代æ¿ãšããŠäœ¿çšããããšãã§ããŸãã æ³šå°ã¯ãçµå£è¬æäžã®åœ¢æ ãšèããããè¬ã¯ããæ¥éã«åžåãããããšãå¯èœã«ããŸããã¢ããªã«ã®æ³šå°å¯èœãªè¬å€ã®åžå Žã¯è©äŸ¡ããããšæšå®ãããŸã US$ 284.5 ã¡ãŒãã« ãåãåãã 2022幎 å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã㊠4.7%(çšæ) äºå ±æéäž (2022-2030).ãããã£ãŒã« 1. ã¢ããªã«ã®æ³šå°å¯èœãªè¬å€ã®åžå Žã¯äŸ¡å€ãååã®ã¿ã€ãã2022ã«ããå€ã®åèªã®(%)ãå ±æããŸã埪ç°åšçŸæ£ãç³å°¿ç ããããªã©ã®æ ¢æ§çŸæ£ã®å¢å€§ãäºæž¬æéäžã«åžå Žæé·ãä¿ãããšãæåŸ ãããŸããé£çæŽ»ç¿æ £ã®å€åã¯ãèèªãš... ãã£ãšèŠã
ãŠã£ã«ãœã³ç ã¯ãããŸããŸãªäœã«èç©ãããéå°ãªé ã«ãã£ãŠç¹åŸŽä»ãããããŸããªéºäŒçç¡ç§©åºã§ã ãã£ãã·ã¥, ç¹ã«èèã§, è³, ç®ã®ç²ã. ç æ°ã¯é²è¡æ§ã§ãããå·Šãæ²»çãããŠããªãå Žåã¯ãèè(èè)çŸæ£ãäžæ¢ç¥çµç³»æ©èœé害ãããã³æ»ãåŒãèµ·ããå¯èœæ§ããããŸãã ãŠã£ã«ãœã³ç ã®ç æ°ã®åŸŽåãçç¶ã¯éåžžã6æ³ãã45æ³ã®éã«æåã«çŸããŸãããããã圌ãã¯å代ã®å¹Žã®éã«æãé »ç¹ã«å§ãŸããŸãã ãŠã£ã«ãœã³ç ã¯ãè硬å€ãšã¬ã³ã¿ã¯å€æ§ãšããŠç¥ãããŠããŸãã æ©æèšºæãšæ²»çã¯ãæ·±å»ãªé·æé害ãšçåœãè ããå䜵çãé²ããŸãã ãŠã£ã«ãœã³ç ã¯ãåžå°çŸæ£ã®åœå®¶æ©é¢ãInc.(NORD)ã«ãããšããŠã£ã«ãœã³ç ã¯ã... ãã£ãšèŠã
鎚ã¯ç æ°ã«æ¯èŒçèæ§ããããŸãããä»ã®çš®é¡ã®å®¶çŠœã«ææããŠããç æ°ãéã¶ããšãç¥ãããŠããŸãã ããããã¢ãã«ã®äžè¬çãªç æ°ã®ããã€ãã«ã¯ãã¢ãã«ãŠã€ã«ã¹èçãã¢ãã«ãã©ããããã¥ã¬ã·ã¹ãããã³ã¢ãã©æ¯æ§çãå«ãŸããŸãã ãããã®ç æ°ã®å€ãã®ããã®åŠçœ®ããªãã®ã§ãã¢ãã«ãã©ããã¢ãã«èçãªã©ãã¢ãã«ãäºé²ããããšãéèŠã§ãã ãŸããé©åãªããŠãžã³ã°ã管çãææ°ãããã³éŽšãžã®æ é€ãæäŸãããšãããããç æ°ã«ææã«ããããšãã§ããŸããäžççãªã¢ãã«è¬ãšã¯ã¯ãã³åžå Žã¯ã 1,777.0çŸäžå ãåãåãã 2021幎 å±ç€ºäºå® ã«ã°ã¬ ã«ã€ã㊠7.7%(çšæ) äºå ±æéäž (2021-2028).... ãã£ãšèŠã
ç¹å®ã®æ£è ã®å¿ èŠæ§ã«åŸã£ãŠåŠçœ®ãäœæããããã«ç©è³ªãçµåããæ··åãããããŸãã¯å€æŽããããã»ã¹ã¯è¬ç©ã®æ··åãšããŠç¥ãããŠããŸãã æ··åã¯2ã€ä»¥äžã®è¬ãæ··åããããã»ã¹ã§ãã åã ã®ååŠè¬åã¯æ£è ã®ããã«èŠæ±ãããå³å¯ãªåŒ·ãããã³é©é圢æ ã§æ··åãããŸãã é åè¬ã¯ã鿥å»ã®èŠæ±ã«åºã¥ããŠèª¿è£œãããŸãã ç±³åœé£åå»è¬åå±(FDA)ã¯ãäžè¬çã«FDAã®èšåºè©ŠéšãåããŠããè¬ããæãæåãèŠå¶ããæ¿èªãåããã æ£è ãç±³åœé£åå»è¬åå±(FDA)ã®æ¿èªè¬ã§æ²»çã§ããªãå Žåã¯ãé åãè¡ãããŸããç±³åœã®ãªãã£ãµãŒååç©è¬å±åžå Žã§ã¯è©äŸ¡ããããšæšå®ããã US$ 219.2 çŸäž ãåãåãã 2021幎 å±... ãã£ãšèŠã
èçŸæ£ã¯ã(éºäŒå)ãç¶æ¿ãããããŸãã¯ãŠã€ã«ã¹(èçAãèçBãèçC)ãªã©ã®èèãæå·ããéå°ãªã¢ã«ã³ãŒã«æåãåŒãèµ·ããèŠå ã«ãã£ãŠåŒãèµ·ããããŸãã è¥æºãèèã®æå·ã«é¢é£ããŠããŸãã èèã¯ãé£ç©ã®æ¶åãå©ããäœå ã®ç©è³ªã®æ¯æ§ãå¶åŸ¡ããäœã®éèŠãªéšåã§ãã è硬å€ã¯èèã®æå·ã®çµæã§ãããåœãè ããããšãã§ããèé害ã«ã€ãªããããšãã§ããŸããéã¢ã«ã³ãŒã«èèªèçŸæ£ãèçãªã©ã®æ ¢æ§èçŸæ£ã®å¢å€§çã¯ãè¥æºã2åç³å°¿ç (DM)ãªã©ã®çæŽ»ç¿æ £ç ã«ããäžæ±å°åã«ããã倧éå£ã®æ ç¹ã§ãèçŸæ£ã®æ²»çã«äœ¿çšãããè¬ã®éèŠãä¿ãããšãæåŸ ãããåžå Žæé·ãä¿é²ããŸããäžæ±ããã³ãã«ã³ã®æ ¢æ§èçŸæ£(CLD... ãã£ãšèŠã
ãªã«ãã¡ã³ãã©ãã°åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎äžçã®Orphanã®è¬å€ã®åžå Žã®ãµã€ãºã¯USDã§äŸ¡å€ããããšæšå®ãããŸã 2026幎ã§175.4åç±³ãã«ã«éããèŠèŸŒã¿ 2033幎ã2026幎ãã9.3%ã®ååç©å¹Žéæé·ç(CAGR)ãå±ç€º 2033幎é ãããã£ãŒã«ãªãŒãã¡ã³ãã©ãã°åžå Žã¯ãåžå°ãªæ²»çã®éçºã«çŠç¹ãåœãŠãŠããŸã å°ããªæ£è éå£ã«åœ±é¿ãäžããçŸæ£ã æ¿åºãšæ¿åº èŠå¶æ©é¢ã¯ãçšéã¯ã¬ãžãããåžå Žãªã©ã®ã€ã³ã»ã³ãã£ããæäŸããŸã å»è¬åäŒç€Ÿã奚å±ããããã®ç¬å çãã€è¿ éãªæ¿èª ãããã®çæ³ã«æè³ããã åžå°äŸ¡å€ã®é«ãŸã ç æ°ããã€ãªãã¯ãããžãŒã®é²æ©ããããŠæé·ã®æè ã... ãã£ãšèŠã
Gonadotropinè§£æŸã®ãã«ã¢ã³(GnRH)ã®ã¢ãŽãã¹ãã¯åandrogensããã³estrogensãã倧ããå®å šããã³å¹åã®ãããã£ãŒã«ãæã€ããã«èæ ®ãããå»åŠã®é³é ç©ãéæããããŸããŸãªçæ³ã®éã§ãããŸãã ããã«ãè¬ã¯äž»ã«æ£è ãå¿«é©ã«ããçæŽ»ã®è³ªãæ¹åãããŸãåŠçœ®ã®è²»çšãåæžããäœéè§£æŸã®å ¬åŒã®åœ¢æ ã®ããã£ã§æ³šå ¥ãããŸãã ã»ãšãã©ã®æé, åç«è ºããã¯ããã¹ãã¹ããã³ãã«ã¢ã³ãå¢å ãããããšã§é²è¡. ãŸãããã¹ãã¹ããã³ã®çç£ã¯ãæè¡çã«çŸäžžãåãé€ãããŸãã¯è¬ç©çæ³ãéããŠåæ¢ããããšãã§ããŸãã Triptorelinã¯GnRHã®ã¢ãŽãã¹ãã§ããã¹ãã¹ããã³ãäœãããè§Šæ... ãã£ãšèŠã
ç¥çµçã®çã¿ã¯ãæ«æ¢¢ç¹ç¶(AβãAÎŽãCç¹ç¶)ãäžå€®ãã¥ãŒãã³ãããã³äººå£ã®7-10%ã«åœ±é¿ãåãŒããœãããŒãœã¹çè«ã·ã¹ãã ã®ç å€ãŸãã¯ç æ°ã«ãã£ãŠåŒãèµ·ããããã ç¥çµçã®çã¿ã®è€æ°ã®åå ãç¹å®ããããã®èå»¶ã¯ãäžççãªäººå£ãèåãããç³å°¿ç ã®çºççã®å¢å ãæåŸ ãããŠããŸãã ç¥çµçã®çç¶ãæªãçµæãããã³å°é£ãªæ²»çã®æ±ºå®ã®è€éãã¯ãæ ¢æ§ç¥çµçã®è² æ ã«è²¢ç®ããŸãã æãéèŠãªã®ã¯ãç¥çµçã®çã¿ãæã€äººã ã¯ãå¢å ãããè¬ã®åŠæ¹ããã«ã¹ã±ã¢ãããã€ããŒãžã®é »ç¹ãªèšªåããªãã³ã«çã¿ãææçããã®çœ¹æ£çãªã©ã®ç掻ã®è³ªãäœäžããŠããŸãã é害ã«ãããããããç¥çµé害ã®ç çåŠãçè§£ããããã®é²æ©ã¯ã驿°... ãã£ãšèŠã
é«èçã¯ãé«èçãšãåŒã°ãããã»ãªã¢é«èã«ãã£ãŠåŒãèµ·ããããŸãã ãã®çŸæ£ã¯ãæªæ²»çãã¯ã¯ãã³ãä»ããäºé²å¯èœãªå Žåã髿»äº¡çãæããäžççãªé«èçŸæ£æ²»çåžå Žã¯ãè©äŸ¡ããããšæšå®ããã 3,754.1çŸäžå ãåãåãã 2021幎 å±ç€ºäºå® ã«ã°ã¬ äºæž¬æéã®12.6%ä»¥äž (2021-2028).ãããã£ãŒã« 1. ã°ããŒãã«ã¡ã³ã¿ã³ã«ã« çŸæ£æ²»çåžå Žã·ã§ã¢(%) å€ãå°åå¥ã2021幎è¬ã®æ¿èªã®å¢å ã¯ãäºæž¬æéã«ããã£ãŠåžå Žæé·ãä¿é²ããããšãæåŸ ãããŸãããšãã°ã2018幎ãå»è¬åäŒç€Ÿã§ããGlaxoSmithKline Plc.ã¯ãç±³åœé£åå»è¬åå±(Baxsero)ãããåäŸ2ã1... ãã£ãšèŠã
ãžã«ã¯ã¯ãã³ åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎ã°ããŒãã«ãžã«ã¯ã¯ãã³ åžå ŽèŠæš¡ã¯ç±³ãã«ã§è©äŸ¡ããããšæšå®ããã 2026幎ã«420åç±³ãã«ã«éãããšã2033幎ãŸã§ã«1åç±³ãã«ã«éããèŠèŸŒã¿ 2026幎ãã14.2%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎ããããã£ãŒã«ãžã«ã¯ã¯ãã³åžå Žã¯ãããã€ãã®ç¹å®ã® ã¯ã¯ãã³ãžã«ãŠã€ã«ã¹ææã®äºé²ãæšçãšããã¿ã€ãã ã©ã€ãattenuated ZIKV-LAVåè£ãªã©ã®ã¯ã¯ãã³ã¯ã匱ãããããŠã€ã«ã¹æ ªã䜿çšã㊠匷ããé·ç¶ããããå é€ãåºæ¿ããŠäžããã æŽ»æ§ã¯ã¯ãã³(ã¯ã¯ãã³ãå«ã) ZPIV(ZikaæµåãããæŽ»æ§åã¯ã¯ãã³)ã¯ã... ãã£ãšèŠã
Ioversolåžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033ã°ããŒãã«ã€ãªãŒããŒãŸã«åžå ŽèŠæš¡ã¯ãUSD 1.12ã§è©äŸ¡ããããšæšå®ããã 2026 åç±³ãã«ã2033 åç±³ãã«ã«éããèŠèŸŒã¿ 2026幎ãã2026幎ã«ãããŠ7.3%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎ããããã£ãŒã«Ioversolã®åžå Žã¯äž»ã«äœ¿çšãããå¯Ÿç §åªäœãããã¯ãããæã£ãŠããŸã ãåãåãã 蚺æ ã€ã¡ãŒãžã³ã°, ç¬ç«ããå¯Ÿç §ã®ä»£çåºããã³å°éçãå«ã èšç®ããããã¢ã°ã©ãã£(CT)ãšã¢ãã°ã©ãã£ã®æé ã®ããã®åŠæ¹ã Intravenous Ioversolã¯é«ãããã管ããã³åšå®ã®ããã«åºãå©çšãããŠããŸã... ãã£ãšèŠã
ããªãªã¯ã¯ãã³ åžå ŽèŠæš¡ãšäºæž¬ â 2026 â 2033幎äžçã®ããªãªã¯ã¯ãã³ åžå ŽèŠæš¡ã¯è©äŸ¡ããããšæšå®ããã 2026幎ã®USD 4.5åãUSD 7.2åã«éããèŠèŸŒã¿ 2033幎ã2026幎6.3%ã®ååç©å¹Žéæé·ç(CAGR)ãåºå± 2033幎é ãããã£ãŒã«Polioã¯ã¯ãã³åžå Žã¯äž»ã«2ã€ã®äž»èŠãªè£œåã§æ§æãããŠããŸã ã¿ã€ã: ç¡å¹å ããªãªã¯ã¯ãã³ (IPV) ããã³çµå£ããªãªã¯ã¯ãã³(OPV)ã IPVã管çããã æ³šå ¥ã«ãã£ãŠãäžæŽ»æ§ã®ããªãªãŠã€ã«ã¹ãå«ã¿ãã§åºãå©çšãããŠããŸã 匷åãªå®å šãããã¡ã€ã«ã«ãã宿çãªå ç«ããã°ã©ã ã OPVã®ã å£é ã§ãæ¿ããã©ã€ããŠã€ã«ã¹... ãã£ãšèŠã
è³è «çåžå Žãé©å¿çå¥ïŒç¥çµè èœè «ãé«èè «ãäžåäœè «çããã®ä»ïŒåžçªèµ·è è «ãæç¶çްèè «ãªã©ïŒïŒãæ²»çã¿ã€ãå¥ïŒååŠçæ³ïŒã«ã«ã ã¹ãã³ããã¢ãŸããããé åå€ïŒãã ã¹ãã³ãããã«ã«ããžã³ããã³ã¯ãªã¹ãã³ïŒïŒïŒãæšççæ³ïŒããã·ãºãããã©ããã¬ã¯ãããã ãšã³ãã¬ã¯ãããããã®ä» (ãžãããã·ãããããã·ã¿ãã-gqgk ãªã©))ãå ç«çæ³ (ãã¹ã¿ãŒãªãããé¡ç²çãã¯ããã¡ãŒãžã³ãããŒåºæ¿å åããã³ãããªãºãã))ãæµéãã£ãã«å¥ (ç é¢è¬å±ãå°å£²è¬å±ããªã³ã©ã€ã³è¬å±)ãå°åå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãã¢ããªã«)... ãã£ãšèŠã
æœ°çæ§å€§è žçã¯ãççã«åãŒãççæ§è žçŸæ£ã®ã«ããŽãªã§ãããæ¶å管ã®çã¿ã æœ°çæ§é¢ç¯çã¯ã倧ããªè ž(ã³ãã³)ãšç©åœ¢ã®å åŽã®ã©ã€ãã³ã°ã«åœ±é¿ãäžããŸãã éåžžãççã®éç床ã«å¿ããŠçç¶ãåŸã ã«èŠãããŸãã è¬ç©çæ³ã«ãã£ãŠè»œåºŠã®åŸŽåã¯æ²»ãããšãã§ããŸãããéçã®å Žåã«ã¯å€ç§åŠçœ®ã¯å¿ èŠã§ãã æœ°çæ§å€§è žçã¯ã8幎以äžã«ããã£ãŠæç¶ããå Žåãå€§è žããã«ã€ãªããå¯èœæ§ããããŸãã ãã«ã¹ã±ã¢äºé²çãå¢å ãããããšã«ãããæ²»çã®å©ç¹ãæ±ããããã«ããŸããŸããŸãææã«ãªã£ãŠããŠããŸãã äºé²å»çã§ã¯ãè¬ç©ãæ°èŠæ²»çããå€§è žããã®çºçå¯èœæ§ãäœäžãããŸãã é¢é£ããå䜵çã®å¯èœæ§ æœ°çæ§é¢ç¯ç 穎ããããã³... ãã£ãšèŠã
è¡åŸã¹ãã¬ã¹é害(PTSD)ã¯ãèªç¶çœå®³ãæ·±å»ãªäºæ ãæ§çæŽåãããè¡çºãªã©ãçµéšãŸãã¯èšŒäººçã€ãã³ãã«ãã£ãп޻æ§åããã粟ç¥çå¥åº·ç¶æ ã§ãã PTSDã¯ãå šãŠã®å¹Žéœ¢ã®äººã ã«çºçããå¯èœæ§ããããŸãã è¡åŸã®ã¹ãã¬ã¹é害ã®äž»ãªçç¶ã®ããã€ãã¯ãæèãšæ°åã®åŠå®çãªå€åããªãã³ã«ææ çããã³ç©ççåå¿ã®å€åã«äžå¯æ¬ ã§ãã PTSDã®å»åž«ã«ãã£ãŠåŠæ¹ãããäžè¬çãªè¬ã¯ãæãã€è¬ãæäžå®è¬ããã«ãªãã»ãã³ãªã©ã§ãã2022幎(2022幎ïœ2030幎)ã¯ãã°ããŒãã«ãã¹ãã»ãã©ãŠãããã¯ã»ã¹ãã¬ã¹ã»ãã£ã¹ãªãŒããŒã»ããªãŒãã¡ã³ãã»ããŒã±ãããç±³åœ$ 1034.3åã§è©äŸ¡ãããäºæž¬æé(2022幎ïœ20... ãã£ãšèŠã
ããšãã³ç åC(NPC)ã¯ããªãœãã«è²¯èµé害ã®äžçš®ã§ãããŸããªéºäŒçé害ã§ãã NPCã¯ãè³ãªã©ã®äœã®ç°ãªãçµç¹ã«ãããã³ã¬ã¹ãããŒã«ãä»ã®èèªç©è³ªã®èç©ã«ã€ãªããã NPCã®ç¹å®ã®çç¶ã®çºçã¯äººãã人ãŸã§æ§ã ã§ãã ã»ãšãã©ã®å Žåãçç¶ã¯å°å æã«çŸããŸããããã«ãããé«éœ¢åã«äŒŽãçæŽ»ãè ããå䜵çãåŒãèµ·ãããŸãã NPC 㯠NPC 1 éºäŒåãš NPC 2 éºäŒåã®å€ç°ã®çµæãšããŠçºçããèªåååž°çã«ç¶æ¿ãããŸããã°ããŒãã«ããšãã³ç è¬Cåæ²»ç åžå Ž - ã³ãããŠã€ã«ã¹ã®åœ±é¿(COVID-19)ãã³ãããã¯ã³ãããŠã€ã«ã¹(COVID-19)çºçã¯ã2019幎12æ31æ¥ãæŠæŒ¢ãäžåœã§æå... ãã£ãšèŠã
ãŸã©ããã¯ã¹åžå Žã補åã¿ã€ãå¥ïŒãŸã©ããã¯ã¹ 3.6 mg ããã³ãŸã©ããã¯ã¹ 10.8 mgïŒãçšé/é©å¿çå¥ïŒåç«è ºãããä¹³ãããåå®®å èçãææ¥ææ©çºçããã®ä»ã®ãã«ã¢ã³æåæ§çŸæ£ïŒããšã³ããŠãŒã¶ãŒå¥ïŒç é¢ãè «çç§ã¯ãªããã¯ãå°éæ²»çã»ã³ã¿ãŒãç ç©¶ããã³åŠè¡æ©é¢ïŒãå°çå¥ïŒåç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžç±³ïŒ æ±éšãã¢ããªã«)... ãã£ãšèŠã
ã³ãã³ã¯ã¬ã³ãºåžå Žã補åã¿ã€ãå¥ïŒããŒãçµè žæŽæµå€ãç¹ç¶ããŒã¹ã®æŽæµå€ããããã€ãªãã£ã¯ã¹ãµããªã¡ã³ããæµ£è žããã³æŽæµããããªã©ïŒã圢æ å¥ïŒé å€ããã³ã«ãã»ã«ãç²æ«ããã³é£²ææ··åç©ãããã³æ¶²äœæº¶æ¶²ïŒãçšéå¥ïŒå人ãç é¢ããã³ãŠã§ã«ãã¹æœèšããã³æœèšïŒãæµéãã£ãã«å¥ïŒãªã³ã©ã€ã³å°å£²ãè¬å±ããã³ãã©ãã°ã¹ãã¢ãã¹ãŒããŒããŒã±ããããã³ãã®ä»ïŒ ãã€ããŒããŒã±ãããããã³å°éå»çåº)ããšã³ããŠãŒã¶ãŒ (æäºº (18 ïœ 45 æ³)ãäžå¹Ž (46 ïœ 65 æ³)ãããã³é«éœ¢è (65 æ³ä»¥äž))ãå°çå¥ (åç±³ããšãŒããããã¢ãžã¢å€ªå¹³æŽãã©ãã³ã¢ã¡ãªã«ãäžæ±ãããã³ã¢ããªã«)... ãã£ãšèŠã